No Known Mutations

IRB# 19498
Study of BA3021 in patients with advanced solid tumors

IRB# 18498
Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

IRB# 19752
Study of Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

IRB# 18303
Study of Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Disease in Solid Tumors

IRB# 19277
A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors

IRB# 19388
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

IRB# 18304
Lenvatinib + Keytruda in Subjects with Solid Tumors

IRB# 21194
A phase 1 study of SGN-CD228A in select advanced solid tumors

IRB# 21508
Study of ORIC-101 in Combination With Anticancer Therapy

IRB# 21464
A Study of mRNA-2752 for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

IRB# 21766
A Phase 1b study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

IRB# 22792
A Phase 1b Dose Escalation Study to evaluate GS-3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors

IRB# 22082
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

IRB# 22760
Study of Magrolimab in Participants With Solid Tumors

IRB# 23157
Study of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

IRB# 23236
Study of SGN-STNV in Advanced Solid Tumors

IRB# 22797
Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

IRB# 21795
A Phase 1 Study of SNDX-6352 with or without Durvalumab in Subjects with Solid Tumors

12/16/2021

http://www.ohsu.edu/research/rda/so/knight.php

Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

Key

- Open for Enrollment
- In Development
- Enrollment on Hold
Phase 1 Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

<table>
<thead>
<tr>
<th>Tumor Mutation Burden - High</th>
<th>Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway</th>
<th>Fusion-NTRK (previously treated)</th>
<th>RET Mutations</th>
</tr>
</thead>
</table>
| IRB# 18788  
Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TM8-H) | IRB# 17674  
Loxo-195 in fusion-NTRK (previously treated) solid tumors | IRB# 16676  
BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors | IRB# 18164  
A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity |

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

12/16/2021

http://www.ohsu.edu/research/rda/sd/so/knight.php
| IRB 21998 | A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation |
| IRB 22223 | A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors |
| IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors |
| IRB 23745 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRISTAL-14) |
| IRB 23757 coming soon |
| IRB 22902 | A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION |
| IRB 22925 | A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors |
| IRB 22986 | An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer |

**Key**
- **Open for Enrollment**
- **In Development**
- **Enrollment on Hold**

http://www.ohsu.edu/research/rda/so/knight.php